Nucl Med Mol Imaging.  2018 Feb;52(1):80-81. 10.1007/s13139-017-0508-3.

Injection of Botulinum Toxin for Preventing Salivary Gland Toxicity after PSMA Radioligand Therapy: an Empirical Proof of a Promising Concept

• Baum RP
• Langbein T
• Singh A
• Shahinfar
• Schuchardt C
• Volk GF
• Kulkarni H

• KMID: 2407306
• DOI: http://doi.org/10.1007/s13139-017-0508-3

Abstract

The dose-limiting salivary gland toxicity of ²²âµAc-labelled PSMA for treatment of metastatic, castration-resistant prostate cancer remains unresolved. Suppressing the metabolism of the gland by intraparenchymal injections of botulinum toxin appears to be a promising method to reduce off-target uptake. A ⁶⁸Ga-PSMA PET/CT scan performed 45 days after injection of 80 units of botulinum toxin A into the right parotid gland in a 63-year-old patient showed a decrease in the SUVmean in the right parotid gland of up to 64% as compared with baseline. This approach could be a significant breakthrough for radioprotection of the salivary glands during PSMA radioligand therapy.

Keyword

Prostate cancer; PSMAradioligands; Salivary glands; Positronemissiontomography; Botulinumtoxin; Xerostomia

MeSH Terms

Botulinum Toxins*
Humans
Metabolism
Methods
Middle Aged
Parotid Gland
Positron-Emission Tomography and Computed Tomography
Prostatic Neoplasms
Salivary Glands*
Xerostomia
Botulinum Toxins